Evidence map›Paper›PMID 42768189›Full record

ReviewNature reviews. Neurology2026

The emerging role of microbiota in neuro-oncology.

Golnaz Morad, Rebecca A Soto, Nadim J Ajami, Sherise D Ferguson, Jennifer A Wargo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Golnaz MoradDepartment of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. golnaz.morad@moffitt.org.ORCID http://orcid.org/0000-0002-9460-618X
Rebecca A SotoPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nadim J AjamiPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3808-8576
Sherise D FergusonDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer A WargoPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.ORCID http://orcid.org/0000-0003-3438-7576

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary and metastatic brain tumours are associated with poor clinical outcomes, largely owing to limited therapeutic advances and an incomplete understanding of brain tumour biology. Increasing evidence suggests that microbial communities play an important part in shaping systemic immunity and tumour biology. Microbes and microbial by-products from the gut and oral cavity can influence the central nervous system through the gut-oral-brain axis, providing potential mechanisms by which distant microbes shape the brain tumour microenvironment. A growing body of literature has identified distinct gut and oral microbial signatures associated with brain tumours and demonstrated that microbiota modulation can influence tumour growth and treatment response in preclinical models. In addition, emerging clinical data indicate that primary and metastatic brain tumours can harbour intracellular microbial elements. In this Review, we summarize current knowledge on the roles of the gut and oral microbiota and intratumoural microbial elements in brain tumour biology and treatment response. We present the technical challenges inherent to microbial studies in brain tumours due to low biomass and the high risk of contamination, and discuss key clinical, experimental and computational considerations needed for rigorous experimental design and standardized methodologies. Last, we discuss translational opportunities and future directions for moving the field towards clinical impact.

Identifiers

PMID42768189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.